PL360707A1 - Kompozycje zawierające składniki o działaniu agonisty alfa-2-adrenergicznego - Google Patents

Kompozycje zawierające składniki o działaniu agonisty alfa-2-adrenergicznego

Info

Publication number
PL360707A1
PL360707A1 PL36070701A PL36070701A PL360707A1 PL 360707 A1 PL360707 A1 PL 360707A1 PL 36070701 A PL36070701 A PL 36070701A PL 36070701 A PL36070701 A PL 36070701A PL 360707 A1 PL360707 A1 PL 360707A1
Authority
PL
Poland
Prior art keywords
adrenergic agonist
alpha
components
agonist components
compositions containing
Prior art date
Application number
PL36070701A
Other languages
English (en)
Inventor
Orest Olejnik
Edward D.S. Kerslake
Original Assignee
Allergan Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22814143&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL360707(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc. filed Critical Allergan Inc.
Publication of PL360707A1 publication Critical patent/PL360707A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/734—Alginic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL36070701A 2000-07-14 2001-07-09 Kompozycje zawierające składniki o działaniu agonisty alfa-2-adrenergicznego PL360707A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21820000P 2000-07-14 2000-07-14
PCT/US2001/021552 WO2002005853A2 (en) 2000-07-14 2001-07-09 Compositions containing alpha-2-adrenergic agonist components

Publications (1)

Publication Number Publication Date
PL360707A1 true PL360707A1 (pl) 2004-09-20

Family

ID=22814143

Family Applications (1)

Application Number Title Priority Date Filing Date
PL36070701A PL360707A1 (pl) 2000-07-14 2001-07-09 Kompozycje zawierające składniki o działaniu agonisty alfa-2-adrenergicznego

Country Status (19)

Country Link
US (4) US6627210B2 (pl)
EP (1) EP1365811A2 (pl)
JP (3) JP4927298B2 (pl)
KR (1) KR100757656B1 (pl)
CN (2) CN100569291C (pl)
AR (1) AR033539A1 (pl)
AU (2) AU7326901A (pl)
BR (1) BR0109317A (pl)
CA (1) CA2402405C (pl)
HU (1) HUP0303197A3 (pl)
IL (2) IL151530A0 (pl)
MX (1) MXPA02008930A (pl)
NO (1) NO333367B1 (pl)
NZ (1) NZ521185A (pl)
PL (1) PL360707A1 (pl)
RU (1) RU2311928C2 (pl)
TW (1) TWI287998B (pl)
WO (1) WO2002005853A2 (pl)
ZA (1) ZA200207413B (pl)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8858961B2 (en) 2000-07-14 2014-10-14 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US20050026924A1 (en) * 2000-07-14 2005-02-03 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
CA2416169C (en) * 2000-07-14 2008-09-23 Allergan, Inc. Compositions containing therapeutically active components having enhanced solubility
PL360707A1 (pl) * 2000-07-14 2004-09-20 Allergan Inc. Kompozycje zawierające składniki o działaniu agonisty alfa-2-adrenergicznego
AU2011250793B2 (en) * 2000-07-14 2012-11-29 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US20040214829A1 (en) * 2000-07-14 2004-10-28 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
CA2446705C (en) * 2001-05-03 2012-03-06 David F. Woodward Compositions of quinoxaline-based therapeutic agents and fatty acids having enhanced pharmacokinetic characteristics
US20020198209A1 (en) * 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US6753017B2 (en) * 2001-11-07 2004-06-22 Jrs Pharma Lp Process for preparing dry extracts
US7642258B2 (en) * 2002-04-19 2010-01-05 Allergan, Inc. Combination of brimonidine and timolol for topical ophthalmic use
US7030149B2 (en) 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
US6982079B2 (en) * 2002-04-26 2006-01-03 Allergan, Inc. Compositions for treating hyperemia
US20040266776A1 (en) * 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
DE60327335D1 (de) * 2002-10-08 2009-06-04 Allergan Inc Alpha 2b oder 2b/2c adrenozeptor-agonisten zur behandlung von morbus alzheimer und morbus parkinson
JP2006504741A (ja) * 2002-10-08 2006-02-09 アラーガン、インコーポレイテッド 痴呆およびパーキンソン病の処置における（２−イミダゾリン−２−イルアミノ）キノキサリンの使用方法
US20040137079A1 (en) * 2003-01-08 2004-07-15 Cook James N. Contact lens and eye drop rewetter compositions and methods
US20040191332A1 (en) * 2003-03-27 2004-09-30 Allergan, Inc. Preserved ophthalmic compositions
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
CA2534484A1 (en) * 2003-08-07 2005-02-17 Allergan, Inc. Compositions for delivery of therapeutics into the eyes and methods for making and using same
WO2005041869A2 (en) * 2003-10-24 2005-05-12 Josef Rettenmaier & Soehne Gmbh & Co., Kg Process for co-spray drying agents with dry silicified mcc
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8529927B2 (en) * 2004-04-30 2013-09-10 Allergan, Inc. Alpha-2 agonist polymeric drug delivery systems
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US8425929B2 (en) * 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US20050244463A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US8673341B2 (en) * 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
CA2505836C (en) * 2004-05-06 2013-08-27 Alcon Inc. Topical brimonidine tartrate formulations that lack chlorine dioxide
JP4955543B2 (ja) * 2004-05-25 2012-06-20 サンズローザ ファーマシューティカル ディヴェロップメント インコーポレイテッド 炎症性皮膚疾患を治療又は予防するための化合物、製剤及び方法
JP4789454B2 (ja) * 2004-12-03 2011-10-12 株式会社キーエンス 蛍光顕微鏡
US20060228487A1 (en) * 2005-04-11 2006-10-12 J. Rettenmaier & Söehne GmbH + Co. KG Methods of combining active agents with augmented microcrystalline cellulose
US8003624B2 (en) * 2005-08-25 2011-08-23 Schering Corporation Functionally selective ALPHA2C adrenoreceptor agonists
BRPI0615307A2 (pt) * 2005-08-25 2009-08-04 Schering Corp agonistas de adrenorreceptor alfa2c
RU2008110902A (ru) * 2005-08-25 2009-09-27 Шеринг Корпорейшн (US) Агонисты адренорецепторов альфа а2с
US7700592B2 (en) * 2005-08-25 2010-04-20 Schering Corporation α2C adrenoreceptor agonists
WO2007056457A2 (en) 2005-11-09 2007-05-18 Combinatorx, Incorporated Methods, compositions, and kits for the treatment of medical conditions
US20070238732A1 (en) * 2006-04-10 2007-10-11 Allergan, Inc. Brimonidine and timolol compositions
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
PT2252290T (pt) * 2008-02-15 2018-02-14 Bone Therapeutics Sa Composição farmacêutica para utilização no tratamento e/ou prevenção de doenças osteoarticulares
US9415036B2 (en) * 2008-02-15 2016-08-16 Bone Therapeutics Pharmaceutical composition for use in the treatment or prevention of osteoarticular diseases
US7842714B2 (en) * 2008-03-03 2010-11-30 Allergan, Inc. Ketorolac tromethamine compositions for treating ocular pain
US9192571B2 (en) 2008-03-03 2015-11-24 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
US20110003823A1 (en) * 2008-08-01 2011-01-06 Alpha Synergy Development, Inc. Compositions and methods for treatment of diseases and conditions associated with vasodilation and/or vascular leakage
US20100028266A1 (en) * 2008-08-01 2010-02-04 Alpha Synergy Development. Inc. Composition and methods for treating allergic response
US20120156244A1 (en) * 2008-08-01 2012-06-21 Alpha Synergy Development Inc. Nasal Compositions and Uses Thereof
US20100202979A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of pulmonary diseases and conditions
US20100203165A1 (en) 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
US20100197694A1 (en) * 2008-08-01 2010-08-05 Gerald Horn Compositions and methods for treatment of diseases and conditions with increased vascular permeability
US12246013B2 (en) 2008-08-01 2025-03-11 Eye Therapies Llc Vasoconstriction compositions and methods of use
US8952011B2 (en) 2008-08-01 2015-02-10 Eye Therapies Llc Compositions and methods for the treatment of nasal conditions
EP2323734A1 (en) * 2008-08-04 2011-05-25 Schering Corporation Cyclopropylchromene derivatives as modulators of the alpha-2c receptor
EP2356106A1 (en) 2008-10-07 2011-08-17 Schering Corporation Biaryl spiroaminooxazoline analogues as alpha2c adrenergic receptor modulators
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
US8987270B2 (en) 2009-07-27 2015-03-24 Eye Therapies Llc Formulations of selective alpha-2 agonists and methods of use thereof
PH12012500928A1 (en) 2009-11-09 2012-11-26 Allergan Inc Compositions and methods for stimulating hair growth
US20110152271A1 (en) * 2009-12-17 2011-06-23 Gerald Horn Compositions and methods for ophthalmic delivery of nasal decongestants
US9522153B2 (en) 2009-12-22 2016-12-20 Allergan, Inc. Compositions and methods for lowering intraocular pressure
EP3085358B1 (en) 2010-01-22 2017-11-01 Allergan, Inc. Intracameral sustained release therapeutic agent implants
US8513247B2 (en) 2010-03-26 2013-08-20 Galderma Laboratories, L.P. Methods and compositions for safe and effective treatment of erythema
US8445526B2 (en) 2011-02-03 2013-05-21 Glaucoma & Nasal Therapies Llc Compositions and methods for treatment of glaucoma
PH12014500783A1 (en) 2011-10-19 2014-05-12 Galderma Sa Method of reducing facial flushing associated with systemic use of phosphodiesterase type 5 inhibitors
CN109602691A (zh) 2013-02-15 2019-04-12 阿勒根公司 持续药物递送植入物
US8999938B2 (en) 2013-06-21 2015-04-07 Gnt Llc Ophthalmic lipophilic drug delivery vehicle formulations
CN105682645B (zh) 2013-10-31 2019-09-06 阿勒根公司 含前列腺酰胺的眼内植入物及其使用方法
ES2818073T3 (es) * 2013-12-24 2021-04-09 Sentiss Pharma Private Ltd Solución oftálmica de tartrato de brimonidina tópica
KR20170129823A (ko) * 2015-03-19 2017-11-27 알러간, 인코포레이티드 브리모니딘 및 티몰롤의 고정된 용량 조합
MX2019001633A (es) 2016-08-12 2019-09-18 Silk Tech Ltd Proteina derivada de la seda para el tratamiento de la inflamacion.
EP3962478A1 (en) 2019-05-01 2022-03-09 Clexio Biosciences Ltd. Methods of treating pruritus
EP4057941A4 (en) 2019-11-15 2024-05-29 Silk Technologies Ltd. Stable formulations of silk-derived protein
KR102678138B1 (ko) 2022-09-29 2024-06-25 주식회사태준제약 브리모니딘을 포함하는 안과용 조성물
KR20250049934A (ko) 2023-10-05 2025-04-14 주식회사태준제약 브리모니딘을 포함하는 안과용 조성물

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1154119B (de) * 1961-11-30 1963-09-12 Boehringer Sohn Ingelheim Verfahren zur Herstellung von 2-(2', 4', 6'-Trimethylbenzyl)-1, 3-diazacyclopenten-(2) und seinen Salzen
US3278447A (en) 1963-12-02 1966-10-11 Cloro Bac Products Inc Process for stabilizing chlorine dioxide solution
BE795970A (fr) 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4530920A (en) 1983-11-07 1985-07-23 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH agonist
US4806556A (en) 1985-12-12 1989-02-21 Regents Of The University Of Minnesota Gut-selective opiates
US5719197A (en) 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5607698A (en) 1988-08-04 1997-03-04 Ciba-Geigy Corporation Method of preserving ophthalmic solution and compositions therefor
US5202128A (en) 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
CA2007181C (en) 1989-01-06 1998-11-24 Angelo Mario Morella Sustained release pharmaceutical composition
JPH085779B2 (ja) * 1989-09-22 1996-01-24 杏林製薬株式会社 フレロキサシン点眼液
US5352796A (en) 1989-10-30 1994-10-04 The Salk Institute For Biological Studies Amino acids useful in making GnRH analogs
US5021416A (en) * 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
US5215991A (en) * 1990-01-26 1993-06-01 Allergan, Inc. Combination of selective alpha-adrenergic agonists and Na+ /H+ ex
GB9017353D0 (en) 1990-08-08 1990-09-19 Merck Sharp & Dohme Chemical process
IT1252692B (it) * 1991-11-27 1995-06-23 Zambon Spa Composizione farmaceutica per uso oftalmico contenente un antiinfiammatorio non steroideo ed un decongestionante come principi attivi
JPH05271053A (ja) * 1992-03-27 1993-10-19 Lion Corp 安定な点眼剤
US5459133A (en) * 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
AU6124494A (en) 1993-01-28 1994-08-15 University Of Iowa Research Foundation, The Ophthalmic uses of signa agonists
GB9310965D0 (en) * 1993-05-27 1993-07-14 Ucb Sa 2-hydroxy-3-(1h-imidazol-4-yl)alkyl)benzenecarboximidamides
WO1995010280A1 (en) 1993-10-13 1995-04-20 Allergan Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
SK77396A3 (en) * 1993-12-17 1997-01-08 Procter & Gamble 6-(2-imidazolinylamino)quinoxaline compounds useful as alpha-2 adrenoceptor agonists
US5994110A (en) 1995-02-10 1999-11-30 Mosbach; Klaus Methods for direct synthesis of compounds having complementary structure to a desired molecular entity and use thereof
US6294563B1 (en) * 1994-10-27 2001-09-25 Allergan Sales, Inc. Combinations of prostaglandins and brimonidine or derivatives thereof
US5856329A (en) * 1995-06-28 1999-01-05 Allergan Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury
ZA965837B (en) 1995-07-11 1997-01-31 Merck & Co Inc A triazolylmethyl-indole ethylamine bisulfate salt
EP0834308A1 (en) 1996-09-30 1998-04-08 LG Chemical Limited Ophthalmic formulation for treating myopia comprising dopamine agonist and cyclodextrin
EP0975607A1 (en) 1997-04-18 2000-02-02 Abbott Laboratories A process for the preparation of highly pure 6,7-dichloro-5- nitro-2,3-dihydroquinoxaline-2,3-dione
MY116782A (en) * 1997-12-22 2004-03-31 Otsuka Pharma Co Ltd Water-soluble eye drop
AU2870899A (en) 1998-02-26 1999-09-15 Abbott Laboratories Oral formulation for hydrophilic drugs
EP1069913B1 (en) 1998-04-07 2003-07-23 Alcon Laboratories, Inc. Gelling ophthalmic compositions containing xanthan gum
AU757896B2 (en) * 1998-09-02 2003-03-13 Allergan, Inc. Preserved cyclodextrin-containing compositions
WO2000019981A1 (en) 1998-10-08 2000-04-13 Karagoezian Hampar L Synergistic antimicrobial, dermatological and ophthalmic preparations containing chlorite and hydrogen peroxide
IN185228B (pl) * 1999-02-03 2000-12-09 Bakulesh Mafatlal Dr Khamar
PL360707A1 (pl) * 2000-07-14 2004-09-20 Allergan Inc. Kompozycje zawierające składniki o działaniu agonisty alfa-2-adrenergicznego
CA2416169C (en) * 2000-07-14 2008-09-23 Allergan, Inc. Compositions containing therapeutically active components having enhanced solubility

Also Published As

Publication number Publication date
RU2311928C2 (ru) 2007-12-10
NO20024221D0 (no) 2002-09-04
KR20030017500A (ko) 2003-03-03
CN100569291C (zh) 2009-12-16
HUP0303197A3 (en) 2008-03-28
JP2012067128A (ja) 2012-04-05
JP2008231122A (ja) 2008-10-02
US6673337B2 (en) 2004-01-06
JP2004504279A (ja) 2004-02-12
CN101897704B (zh) 2014-10-29
NO333367B1 (no) 2013-05-13
HUP0303197A2 (hu) 2003-12-29
NZ521185A (en) 2005-02-25
CN1460026A (zh) 2003-12-03
KR100757656B1 (ko) 2007-09-10
US6627210B2 (en) 2003-09-30
CA2402405A1 (en) 2002-01-24
AU2001273269B2 (en) 2005-08-11
IL151530A (en) 2009-05-04
HK1060519A1 (zh) 2004-08-13
WO2002005853A2 (en) 2002-01-24
AR033539A1 (es) 2003-12-26
ZA200207413B (en) 2004-04-08
IL151530A0 (en) 2003-04-10
CN101897704A (zh) 2010-12-01
BR0109317A (pt) 2003-06-17
NO20024221L (no) 2002-10-28
US20040063689A1 (en) 2004-04-01
JP4927298B2 (ja) 2012-05-09
US20030027811A1 (en) 2003-02-06
US20020032201A1 (en) 2002-03-14
WO2002005853A3 (en) 2003-09-12
US20030087893A1 (en) 2003-05-08
TWI287998B (en) 2007-10-11
AU7326901A (en) 2002-01-30
US6641834B2 (en) 2003-11-04
CA2402405C (en) 2008-02-12
EP1365811A2 (en) 2003-12-03
MXPA02008930A (es) 2003-03-31

Similar Documents

Publication Publication Date Title
PL360707A1 (pl) Kompozycje zawierające składniki o działaniu agonisty alfa-2-adrenergicznego
MY136097A (en) Methods for treating osteoarthritis using an estrogen agonist/antagonist
GB2386224A (en) Global electronic trading system
MXPA03011197A (es) Benzoilsufonamidas y sulfonilbenzamidinas que se usan como agentes antitumorales.
EA200300580A1 (ru) Соединения лактама
GB2387696A (en) Real-time odds-based gaming
EA200100773A1 (ru) Замещенные 1-гетероциклические диариламины
ZA200407666B (en) Pyridinoylpiperidines as 5-HTif agonists.
UY26970A1 (es) Uso combinado de inhibidores de acetilcolinesterasa y agonistas inversos de gaba, para el tratamiento de trastornos cognitivos
GB2411467A (en) Method and apparatus for quantifying tissue histology
EP1590471A4 (en) COMPOSITIONS, METHODS AND SYSTEMS OF INFERENCE RELATING TO CATTLE CHARACTERISTICS
WO2003031573A3 (en) Toll-like receptor 3 signaling agonists and antagonists
SG148031A1 (en) Use of cci-779 as an antineoplastic agent
EA200501928A1 (ru) Пирролодигидроизохинолины как ингибиторы pde10
YU80902A (sh) Novi indolin-2-on derivati, njihovo dobijanje i farmaceuski oblici koji ih sadrže
MXPA04003886A (es) Tiofen- y tiazolsulfonamidas como agentes antineoplasticos.
UY26451A1 (es) Procedimiento para la obtención de 1,2,3,4- tetrahidroquinolinas 4-carboxiamino-2-sustituidas
PL351593A1 (en) Substantially oil−free cyclosporin compositions
YU39803A (sh) Jedinjenja piperazinilpirazina kao agonisti ili antagonisti serotonin 5ht-2-receptora
TR200003384T2 (tr) Arginin türevleri kullanılarak oksazolidinon antibakteriyel maddelerin etkisinin arttırılması
MX2007002383A (es) Composiciones que contienen componentes agonistas alfa-2-adrenergicos.
TNSN07137A1 (en) 2-alcoxy-3,4,5-trihydroxy-alkylamides,leur preparation, compositions les contenant et utilisation
MXPA04001785A (es) Benzofurano y derivados de dihidrobenzofurano utiles como agonistas de beta-3 adrenoreceptores.
TWI256304B (en) Pharmaceutical compositions based on azetidine derivatives
MY141607A (en) Lactam compound

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)